Printer Friendly
The Free Library
4,488,990 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Astellas Pharma, Nippon Boehringer Ingelheim Seek Additional Approval for Micardis.


Tokyo, Japan, July 5, 2006 - (JCN) - Astellas Pharma and Nippon Boehringer Ingelheim have filed a joint application for an additional indication of Micardis, an angiotensin angiotensin /an·gio·ten·sin/ (-ten´sin) a decapeptide hormone (a. I) formed from the plasma glycoprotein angiotensinogen by renin secreted by the juxtaglomerular apparatus. It is in turn hydrolyzed by a peptidase in the lungs to form an octapeptide (a. II), which is a powerful vasopressor and stimulator of aldosterone secretion by the adrenal cortex. This is in turn hydrolyzed to form a heptapeptide (a. II receptor blocker, with the Ministry of Health, Labor and Welfare.

The two companies expect that Micardis will become applicable for the treatment of type 2 diabetic nephropathy
analgesic nephropathy  interstitial nephritis with renal papillary necrosis, seen with abuse of analgesics such as aspirin or acetaminophen.
diabetic nephropathy  the nephropathy seen in later stages of diabetes mellitus, with first hyperfiltration, renal hypertrophy, microalbuminuria, and hypertension, and later proteinuria and end-stage renal disease.
. For this application, they have submitted clinical data from INNOVATION, a large-scale clinical study conducted in Japan from January 2003 to November 2006.

Micardis, which is manufactured by Nippon Boehringer Ingelheim and sold by Astellas Pharma in Japan, is currently indicated for the treatment of hypertension.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Geographic Code:9JAPA
Date:Jul 10, 2006
Words:109
Previous Article:LTT Bio-Pharma, Jikei University to Jointly Develop Innovative DDS for Steroids.
Next Article:Bristol-Myers Seeks Additional Approval for Briplatin.



Related Articles
INTERMUNE/BOEHRINGER TO COMMERCIALIZE INTERFERON/GAMMA-1B.
Nippon Boehringer Ingelhemi to Solely Market Alesion Anti-allergic Agent.
Nippon Boehringer Ingelheim, Pfizer Japan Jointly Survey Japanese People Older Than 40 on COPD.
Astellas Pharma Submits NDA for FK506 Immunosuppressant to FDA.
Astellas Pharma Receives FDA Approval for Hyponatremia Drug VAPRISOL.
Nippon Boehringer Ingelheim Begins Promoting Central Nervous System Drugs Lendormin and Bi-Sifrol Via MR-Kun Information Service.
Astellas and Toyama Chemical Announce Basic Licensing Agreement on Domestic Marketing and Joint Development of Quinolone Antibiotic T-3811.
Astellas Establishes New Subsidiary 'Astellas Pharma Chemicals Co., Ltd.'.
Boehringer Ingelheim Vetmedica Japan Begins Distributing Animal Health Products.
Astellas Transfers Three European Plants to Temmler Group, German Pharmaceutical Company.

Terms of use | Copyright © 2008 Farlex, Inc. | Feedback | For webmasters | Submit articles